First report of robot-assisted transperineal fusion versus off-target biopsy in patients undergoing repeat prostate biopsy

Kaufmann, Sascha; Mischinger, Johannes; Amend, Bastian; Rausch, Steffen; Adam, Meike; Scharpf, Marcus; Fend, Falko; Krämer, Ulrich; Notohamiprodjo, Mike; Nikolaou, Konstantin; Stenzl, Arnulf; Bedke, Jens; Kruck, Stephan

doi:10.1007/s00345-016-1970-8

Cited by 16 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings provide a timely evaluation of the utilization of robotic equipment in the prostate cancer diagnostic pathway that utilizes the clinically superior transperineal route. There has been an increased adoption of this technology in units globally but with minimal reported outcomes [9][10][11]. The detection range of csPCa for all the previous similar studies is 50.0%, 52.7%, and 61% which is in-keeping with our overall detection rate of 51.2%.…”

Section: Discussionsupporting

confidence: 82%

A prospective analysis of robotic targeted MRI-US fusion prostate biopsy using the centroid targeting approach

et al. 2019

View full text Add to dashboard Cite

Robotic prostate biopsy is an emerging technology. Recent development of this tool has allowed the performance of a transperineal prostate biopsy allowing pre-programmed standardized biopsy schemes. Prospective data collection was undertaken in 86 consecutive men who underwent robotically assisted transperineal prostate biopsy. All underwent a multi-parametric MRI pre-biopsy with centroid targeting followed by systematic template prostate biopsy. For the purposes of this study, our definition of clinically significant prostate cancer (csPCa) is any Gleason score > 6. Mean (SD) age, median (IQR) PSA, and median (IQR) prostate volume were 64.24 (6.97) years, of 7.79 ng/ml (6.5) and 45.06 cc (28), respectively. Overall, 44 (51.2%) men were diagnosed with csPCa. csPCa was detected in the targeted biopsies alone in 35 (40.1%) men. The addition of the 12-zone template biopsy increased the yield of csPCa for another 9 (10.5%) men. Of these 9 men, the majority (7) harbored primary pattern 3 disease and only 1 was identified to have high-grade disease. Out of these 9 men, 7 of them had the identification of csPCa in the sector, where a target was contained within that zone. Robotic-assisted prostate biopsy in our study has demonstrated a high detection of csPCa when combined with limited near-field sampling. Our study suggests the use of more accurate biopsy schemes such as ring-targeting of lesions to mitigate against systematic and random mathematical errors. Adoption of this tool and biopsy strategy would potentially avoid the increased morbidity associated with whole gland systematic unguided biopsies.

show abstract

Section: Discussionsupporting

confidence: 82%

A prospective analysis of robotic targeted MRI-US fusion prostate biopsy using the centroid targeting approach

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Very recently, we reported the first use of elastic RA‐fusion biopsy in 55 patients with negative prior biopsy, inconspicuous DRE but suspicious mpMRI of the prostate. RA‐TB enabled reliable detection of all high‐risk cancers, whilst off‐target cores detected only one additional clinically significant prostate cancer . In the present series, primary and repeat settings confirmed a high rate of prostate cancer (>60%) and clinically significant prostate cancer (>85%).…”

Section: Discussionsupporting

confidence: 64%

“…Nevertheless, different TB methods (in‐bore, cognitive or software‐based fusion) have been shown to detect more clinically significant and less insignificant prostate cancer compared with SB . Recently, we reported the first use of transperineal robot‐assisted (RA) elastic mpMRI‐TRUS fusion biopsy . In our experience, RA transperineal biopsy offers the potential of standardising the procedure with reproducible quality independent of individual skillsets.…”

Section: Introductionmentioning

confidence: 94%

Targeted vs systematic robot‐assisted transperineal magnetic resonance imaging‐transrectal ultrasonography fusion prostate biopsy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…13 Optimal performance of repeated prostate biopsy remains one of the most controversial dilemmas in urology. 14 Patients with negative diagnosis by TRUS prostate biopsy may need repeat biopsy if the following fi ndings are present: 1. First biopsy pathologic fi ndings of atypical hyperplasia or high level PIN.…”

Section: Discussionmentioning

confidence: 99%

Trans-perineal Prostate Biopsy under Trans-rectal Ultrasound Guidance

Lamichhane

2019

Nep. J. Cancer

View full text Add to dashboard Cite

Prostate cancer is the most common cancer in males in the western world and is an emerging malignancy in eastern world as well. It is less invasive and easily curable in early stages. It requires efficient and accurate diagnosis strategy to detect it early. To date, the standard diagnosis procedure involves a blind biopsy with a high rate of false negative results. Trans-perineal prostate biopsy is re-emerging after decades of being an underused alternative to trans-rectal biopsy guided by trans-rectal ultrasonography. In order to overcome these limitations, the paper proposes the method and advantages of trans-perineal prostate biopsy.

show abstract

First report of robot-assisted transperineal fusion versus off-target biopsy in patients undergoing repeat prostate biopsy

Abstract: This is the first report of transperineal robot-assisted elastic mpMRI-TRUS fusion biopsy. RA-TB of positive MR lesions enabled reliable detection of csPC, while RA-UB in MRI-negative regions is of minor importance.

Cited by 16 publications

References 27 publications

A prospective analysis of robotic targeted MRI-US fusion prostate biopsy using the centroid targeting approach

A prospective analysis of robotic targeted MRI-US fusion prostate biopsy using the centroid targeting approach

Targeted vs systematic robot‐assisted transperineal magnetic resonance imaging‐transrectal ultrasonography fusion prostate biopsy

Trans-perineal Prostate Biopsy under Trans-rectal Ultrasound Guidance

Contact Info

Product

Resources

About